BASKING RIDGE, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for ...

report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Intrahepatic Cholangiocarcinoma market trends in the United States, EU4 (Germany, France, Italy, and ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected by Taiho Oncology to be a specialty pharmacy partner for Lytgobi® (futibatinib), ...

Standard therapies for localized inoperable intrahepatic cholangiocarcinoma (IHCC) are ineffective. Advances in radiotherapy (RT) techniques and image guidance have enabled ablative doses to be ...

Jan 12 (Reuters) - Delcath Systems Inc : * Delcath Systems Inc - patient treatment, data collection for intrahepatic cholangiocarcinoma (ICC) cohort of European Phase 2 HCC/ICC study is ongoing Sign ...

Cholangiocarcinomas are malignant tumors that derive from cholangiocytes of small intrahepatic bile ducts or bile ductules (intrahepatic cholangiocarcinoma; ICC), or of large hilar or extrahepatic ...

Credit must be given to the creator. Only noncommercial uses of the work are permitted.

ICCA accounts for 10–15% of primary liver cancers and is notorious for late-stage diagnosis and resistance to chemotherapy and radiotherapy. While surgical resection offers the best survival outcomes, ...